Innate Pharma to Participate in upcoming investor conferences
12 Novembre 2020 - 7:00AM
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the
“
Company”), today announced that members of its
senior management team are scheduled to participate in the
following upcoming virtual investor conferences.
- Bryan Garnier & Co Virtual European Healthcare
Conference Date: November 17, 2020 Fireside Chat: November
17, 2020 at 10:00 a.m. CET
- Jefferies Virtual London Healthcare Conference
Date: November 18, 2020
- SVB Leerink Oncology 1x1 Day Date: November
19, 2020
- Oddo - Tech40 Digital Forum
5th Edition Date:
November 24-25, 2020
- Evercore ISI 3rd
Annual HealthCONx Date: December 1-3, 2020
Fireside Chat: December 2, 2020 at 8:50-9:10 a.m. ET
A replay of Innate’s presentation at the Bryan
Garnier conference and a live webcast of Innate’s presentation at
the Evercore ISI conference will be accessible through the News
& Events page of the Investors section of the Company’s website
at www.innate-pharma.com.
About Innate Pharma: Innate
Pharma S.A. is a commercial stage oncology-focused biotech company
dedicated to improving treatment and clinical outcomes for patients
through therapeutic antibodies that harness the immune system to
fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca in the US, EU and
Switzerland, was approved by the FDA in September 2018. Lumoxiti is
a first-in class specialty oncology product for hairy cell
leukemia. Innate Pharma’s broad pipeline of antibodies includes
several potentially first-in-class clinical and preclinical
candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding
of natural killer cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris and Nasdaq in the US. Learn more about
Innate Pharma at www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN code Ticker code
LEI |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking
information and risk factors: This press release contains
certain forward-looking statements, including those within the
meaning of the Private Securities Litigation Reform Act of 1995.The
use of certain words, including “believe,” “potential,” “expect”
and “will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Investors Innate Pharma Tel.: +33
(0)4 30 30 30 30 investors@innate-pharma.com |
Media Innate Pharma Tracy Rossin
(Global/US) Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France) Tel.: +33 (0)9
81 87 46 72 innate-pharma@atcg-partners.com |
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024